Хайлтын үр дүнгүүд - Jean‐Marc Ferrero

Үр дүнг сайжруулах
  1. 1
    A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)

    A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative... -н Ahmad Awada, Igor Bondarenko, J. Bonneterre, Elżbieta Nowara, Jean-­Marc Ferrero, Ashish Bakshi, C. Wilke, Martine Piccart

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

    Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity -н S. Beauclair, Patricia Formento, Jean–Louis Fischel, W. Lescaut, R. Largillier, Emmanuel Chamorey, Paul Hofman, Jean-­Marc Ferrero, Gilles Pagès, G. Milano

    Хэвлэсэн 2007
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

    Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial -н Jean-­Marc Ferrero, B. Weber, J.-F. Geay, D. Lepillé, Hubert Orfeuvre, M. Combe, F. Mayer, Bernard Leduc, Hugues Bourgeois, D. Paraïso, Éric Pujade-Lauraine

    Хэвлэсэн 2006
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis

    Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis -н Grazia Arpino, Juan de la Haba-Rodríguez, Jean-­Marc Ferrero, Sabino De Placido, C. Kent Osborne, Dirk Klingbiel, Valentine Revelant, Christine Wohlfarth, Raf Poppe, Mothaffar F. Rimawi

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

    Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma -н Christopher Montemagno, Anaïs Hagege, Delphine Borchiellini, Brice Thamphya, Olivia Rastoin, Damien Ambrosetti, Juan Iovanna, N. Costedoat‐Chalumeau, Camillo Porta, Sylvie Négrier, Jean-­Marc Ferrero, Emmanuel Chamorey, Gilles Pagès, Maeva Dufies

    Хэвлэсэн 2020
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, p... -н Sandra M. Swain, Sung‐Bae Kim, Javier Cortés, Jungsil Ro, Semiglazov Vf, Mario Campone, Eva Ciruelos, Jean-­Marc Ferrero, Andreas Schneeweiß, Adam Knott, Emma Clark, Graham Ross, Mark Benyunes, José Baselga

    Хэвлэсэн 2013
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

    Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients -н Rémy Largillier, Marie‐Christine Etienne‐Grimaldi, Jean–Louis Formento, Joseph Ciccolini, Jean-François Nebbia, A. Ginot, M Francoual, N. Renée, Jean-­Marc Ferrero, Cyril Foa, Moïse Namer, Bruno Lacarelle, G. Milano

    Хэвлэсэн 2006
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer -н Sandra M. Swain, José Baselga, Sung‐Bae Kim, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-­Marc Ferrero, Andreas Schneeweiß, Sarah Heeson, Emma Clark, Graham Ross, Mark Benyunes, Javier Cortés

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

    Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer -н Isabelle Treilleux, Mónica Arnedos, Claire Cropet, Q. Wang, Jean‐Marc Ferrero, Sophie Abadie‐Lacourtoisie, Christelle Lévy, Éric Legouffe, Alain Lortholary, Éric Pujade-Lauraine, Anne-Véronique Bourcier, Jean-Christophe Eymard, D. Spaëth, Thomas Bachelot

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

    Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breas... -н Thomas Bachelot, C. Bourgier, Claire Cropet, Isabelle Ray‐Coquard, Jean-­Marc Ferrero, Gilles Freyer, Sophie Abadie‐Lacourtoisie, Jean‐Christophe Eymard, Marc Debled, Dominique Spaëth, Éric Legouffe, Djelila Allouache, Claude El Kouri, Éric Pujade-Lauraine

    Хэвлэсэн 2012
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE):... -н Sandra M. Swain, Michael S. Ewer, Giuseppe Viale, Suzette Delaloge, Jean-­Marc Ferrero, Mark Verrill, Rámón Colomer, Cláudia Vieira, Theresa L. Werner, Hannah Douthwaite, Denise Bradley, Maeve Waldron-Lynch, Astrid Kiermaier, Jennifer Eng‐Wong, Chau T. Dang

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    Prognostic factors in 1038 women with metastatic breast cancer

    Prognostic factors in 1038 women with metastatic breast cancer -н R. Largillier, Jean-­Marc Ferrero, J. Doyen, Jérôme Barrière, M. Namer, Véronique Mari, A. Courdi, Jean‐Michel Hannoun‐Lévi, F. Ettore, Isabelle Birtwisle‐Peyrottes, C. Balu–Maestro, Pierre Yves Marcy, I. Raoust, M. Lallement, Emmanuel Chamorey

    Хэвлэсэн 2008
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

    Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer -н Carlos H. Barrios, Mei-Ching Liu, Soo Chin Lee, Laurence Vanlemmens, Jean‐Marc Ferrero, Toshio Tabei, Xavier Pivot, Hiroji Iwata, Kenjiro Aogi, Roberto Lugo-Quintana, Nadia Harbeck, Marla Jo Brickman, Ke Zhang, Kenneth A. Kern, Miguel Martín

    Хэвлэсэн 2010
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial

    Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial -н Jean‐Yves Pierga, François‐Clément Bidard, Claire Cropet, Patricia Tresca, Florence Dalenc, Gilles Romieu, Mario Campone, Céline Mahier Aït-Oukhatar, Émilie Le Rhun, Anthony Gonçalvès, Marianne Leheurteur, Julien Dômont, M. Gutierrez, H. Curé, Jean‐Marc Ferrero, C. Labbé-Devilliers, Thomas Bachelot

    Хэвлэсэн 2013
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

    Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial -н Henri Roché, P. Fumoleau, M. Spielmann, Jean-Luc Canon, T. Delozier, Daniel Serin, Michel Symann, Pierre Kerbrat, P Soulié, Françoise Eichler, Patrice Viens, Alain Monnier, A. Vindevoghel, Mario Campone, Marie-Josèphe Goudier, Jacques Bonneterre, Jean-­Marc Ferrero, Anne‐Laure Martin, Jean Genève, Bernard Asselain

    Хэвлэсэн 2006
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study

    MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-... -н Émeline Tabouret, François Bertucci, Jean‐Yves Pierga, Thierry Petit, Christelle Lévy, Jean-­Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Steven Van Laere, Naoto T. Ueno, Yves Toiron, Pascal Finetti, Daniel Birnbaum, Jean‐Paul Borg, Patrice Viens, Olivier Chinot, Anthony Gonçalvès

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

    Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemothera... -н Cora N. Sternberg, Daniel P. Petrylak, Oliver Sartor, J. Alfred Witjes, Tomasz Demkow, Jean-­Marc Ferrero, Jean-Christophe Eymard, S. Falcon, Fabio Calabrò, Nicholas D. James, I. Bodrogi, Peter Harper, Manfred Wirth, William Berry, Michael E. Petrone, Thomas J. McKearn, Mojtaba Noursalehi, Martine George, Marcel Rozencweig

    Хэвлэсэн 2009
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  18. 18
    Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

    Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients -н Emmanuelle Jacquet, Audrey Lardy-Cléaud, Barbara Pistilli, Sophie Franck, Paul Cottu, Suzette Delaloge, Marc Debled, Laurence Vanlemmens, Marianne Leheurteur, Anne‐Valérie Guizard, Lilian Laborde, L. Uwer, William Jacot, D. Berchery, Isabelle Desmoulins, Jean-­Marc Ferrero, G. Perrocheau, Coralie Courtinard, Étienne Brain, Sylvie Chabaud, Mathieu Robain, Thomas Bachelot

    Хэвлэсэн 2018
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  19. 19
    Comparison of Management and Outcomes in <i>ERBB2</i>-Low vs <i>ERBB2</i>-Zero Metastatic Breast Cancer in France

    Comparison of Management and Outcomes in <i>ERBB2</i>-Low vs <i>ERBB2</i>-Zero Metastatic Breast Cancer in France -н Ombline de Calbiac, Amélie Lusque, Audrey Mailliez, Thomas Bachelot, Lionel Uwer, Marie‐Ange Mouret‐Reynier, George Emile, Christelle Jouannaud, Anthony Gonçalvès, Anne Patsouris, Véronique Dièras, Marianne Leheurteur, Thierry Petit, Paul Cottu, Jean-­Marc Ferrero, Véronique D’Hondt, Isabelle Desmoulins, Joana Ribeiro, Anne‐Laure Martin, Jean‐Sébastien Frénel

    Хэвлэсэн 2022
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  20. 20
    Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database

    Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database -н Marcela Carausu, Matthieu Carton, Amélie Darlix, Dominique Pasquier, Marianne Leheurteur, M. Debled, Marie‐Ange Mouret‐Reynier, Anthony Gonçalvès, Florence Dalenc, Benjamin Verret, Mario Campone, Paule Augereau, Jean-­Marc Ferrero, Christelle Lévy, Jean-David Fumet, Claudia Lefeuvre‐Plesse, Thierry Petit, L. Uwer, Christelle Jouannaud, Louis Larrouquère, M. Chevrot, Coralie Courtinard, Luc Cabel

    Хэвлэсэн 2021
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: